- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00527410
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis (LMD)
A Phase I Safety and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent, Progressive or Refractory Neoplastic Meningitis
Study Overview
Detailed Description
Neoplastic meningitis refers to the deposition of malignant cells in the lining (leptomeninges) of the brain and spine. Neoplastic meningitis from solid tumors most often occurs in patients with advanced systemic disease who have failed prior chemotherapy; it is also frequent in patients with CNS parenchymal metastasis. Patient survival remains low, and better treatments are needed to penetrate the blood brain barrier and treat the entire neuraxis.
RTA 744 is a close chemical analogue of the well characterized anti-cancer agent doxorubicin. Unlike doxorubicin, RTA 744 has shown ability to cross the blood brain barrier and to achieve high concentration in CNS tumor tissue in animal models. Dose escalation will continue as pre-determined until first occurrence of a dose-limiting toxicity. Maximum tolerated dose will be determined as defined in protocol.
Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologic confirmation of primary malignancy. All primary tumor types may be enrolled.
- Neoplastic meningitis/leptomeningeal metastasis refractory to conventional therapy with presence of tumor cells on cytology, OR neuroimaging evidence of leptomeningeal tumor by MRI.
- Not eligible for higher priority clinical trial.
- Have recovered from side effects of any surgical resection.
- A stable dose of steroid for at least 7 days prior to the Gd-MRI.
- Karnofsky Performance Status (KPS) of ≥ 60.
- Laboratory Parameters: ANC ≥ 1.5 x 109/L; Hgb ≥ 9 g/dl; Platelets ≥ 100 x 109/L; AST and ALT ≤ 3.0 x ULN; Serum bilirubin ≤ 1.5 x ULN; Serum creatinine ≤ 1.5 x ULN; 24 hour creatinine clearance ≥ 50 ml/min
- Life expectancy of at least 8 weeks.
- Written informed consent obtained.
Exclusion Criteria:
- Concurrent therapy for leptomeningeal disease or other malignancy.
- Clinical evidence of obstructive hydrocephalus or compartmentalization of CSF flow.
- Cumulative doses: doxorubicin > 450 - 550 mg/m2, epirubicin > 800-1000 mg/m2, idarubicin >130-150 mg/m2 and daunorubicin > 400-550 mg/m2.
- Anticonvulsant medications or other types of medications which are known to induce the CYP450 enzymes.
- Pregnancy or breast feeding, or adults (male or female) of reproductive potential not employing an effective method of birth control
- Total 24 hour urinary protein > 500 mg.
- Concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study
- Impaired cardiac function, other significant prior cardiac disease or arrhythmia of any type
- Myocardial infarction ≤ 6 months prior
- History of CHF or arrhythmias
- Therapeutic doses of anticoagulant therapy (prophylactic dosing is allowed)
- Investigational drugs less than 4 weeks prior; intrathecal chemotherapy within 2 weeks prior; systemic cytotoxic chemotherapy within 4 weeks prior (6 weeks for nitrosourea or mitomycin-C or 2 weeks for vincristine); radiation therapy within 2 weeks prior; any medication known to cause QT interval prolongation
- Any surgery <2 weeks prior
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RTA 744
RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks).
Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).
|
Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml.
The drug is mixed in D10W and infused over 2 hours on three consecutive days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the tolerability of RTA 744 Injection in patients with leptomeningeal disease (LMD) secondary to any type of primary tumor.
Time Frame: evaluation at end of cycle 1 for each cohort
|
evaluation at end of cycle 1 for each cohort
|
Characterize the multiple-dose pharmacokinetics of RTA 744 in plasma and CSF in a selected group of 6-10 patients who will receive RTA 744 at or near the maximum tolerated dose (MTD).
Time Frame: end of study
|
end of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Document any potential antitumor activity.
Time Frame: after every even numbered treatment cycle
|
after every even numbered treatment cycle
|
Correlate pharmacokinetic information with clinical (efficacy and safety) responses.
Time Frame: end of study
|
end of study
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RTA 744-C-0601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leptomeningeal Carcinomatosis
-
The First Hospital of Jilin UniversityThe Second Hospital of Hebei Medical University; Second Affiliated Hospital... and other collaboratorsActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterFred Hutchinson Cancer CenterActive, not recruitingLeptomeningeal MetastasesUnited States
-
Massachusetts General HospitalBristol-Myers SquibbCompleted
-
Memorial Sloan Kettering Cancer CenterCenter for Experimental Therapeutics; F.M. KIRBY FOUNDATIONRecruitingLeptomeningeal MetastasesUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedLeptomeningeal MetastasesUnited States
-
West China HospitalNot yet recruitingNSCLC Associated With Leptomeningeal Metastases
-
The First Hospital of Jilin UniversityCompletedLeptomeningeal MetastasesChina
-
Angiochem IncNot yet recruitingBrain Metastases | Leptomeningeal Metastases | HER2-negative Breast Cancer | Leptomeningeal Carcinomatosis
-
Biocept, Inc.ICON plcTerminatedBreast Cancer | Non-Small Cell Lung Cancer | Leptomeningeal Disease | Leptomeningeal Metastasis | Leptomeningeal NeoplasmsUnited States
-
Centre Oscar LambretCompletedBreast Cancer | Leptomeningeal MetastasesFrance
Clinical Trials on RTA 744
-
M.D. Anderson Cancer CenterReata Pharmaceuticals, Inc.TerminatedLymphoma | Leukemia | Solid Tumor | Brain Tumor | Neoplastic MeningitisUnited States
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenTerminatedBrain MetastasesUnited States
-
AbbVieTerminatedAcute Myeloid Leukemia (AML)United States
-
Reata, a wholly owned subsidiary of BiogenWithdrawn
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
Kyowa Kirin Co., Ltd.TerminatedType 2 Diabetes | Chronic Kidney DiseaseJapan
-
M.D. Anderson Cancer CenterReata Pharmaceuticals, Inc.CompletedSolid Tumors | Lymphoid MalignanciesUnited States
-
Reata, a wholly owned subsidiary of BiogenTerminatedLiver DiseaseUnited States
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom